PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Share News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 21.25
Bid: 21.00
Ask: 21.50
Change: -1.25 (-5.56%)
Spread: 0.50 (2.381%)
Open: 22.50
High: 23.50
Low: 21.25
Prev. Close: 22.50
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Australia's AGL says approached by Alinta to buy coal-fired Liddell plant

Wed, 04th Apr 2018 03:02

* No formal offer received - AGL

* Liddell slated to be closed in 2022

* Australia government sought Alinta's interest(Adds fresh Alinta MD quote, background)

SYDNEY, April 4 (Reuters) - Australia's biggest energyproducer AGL Energy Ltd said on Wednesday HongKong-owned rival Alinta Energy has expressed interest in buyingits coal-fired Liddell Power Station, which is slated to beclosed.

AGL wants to shutter the plant in 2022 as part of a phasedexit from coal by 2050 so it can become a purely renewableenergy supplier. But the firm has come under pressure fromAustralia's government to sell the power station instead.

AGL said it received "an approach from Alinta last nightexpressing an interest in entering negotiations" to buy theplant, but that no formal bid had been made.

A formal offer "would be given consideration in order tomeet our obligations to customers and shareholders," AGL said inan emailed statement.

Australia's electricity supply business has become a hotpolitical issue in the past year, after a string of blackoutsand price spikes hit households and major industrial usersincluding miners BHP and Rio Tinto.

That has prompted the country's conservative government toscrap some subsidies for renewable projects. This week abreakaway group of lawmakers called for the government toprovide more financial support for new coal-fired plants.

Alinta's Managing Director Jeff Dimery said in a radiointerview on Wednesday that the government had asked hiscompany, which is owned by Hong Kong's Chow Tai Fook EnterprisesLtd, to consider buying Liddell.

"We stated that we had no objection to owning criticalassets required for stability and reliability in the marketplaceas we transition to a low-carbon economy," Dimery toldAustralian Broadcasting Corp radio.

"We conducted some preliminary analysis that led us to anopinion that, at a commercial rate, there's an opportunityhere," he added.

AGL previously rejected the idea of selling the plantbecause it needs Liddell, located north of Sydney, to maintainsupplies to its own customers ahead of the original 2022 closureplan.

"AGL is relying on Liddell to generate power for ourcustomers until 2022 and we will require its infrastructure forour replacement plans into the future," it said on Wednesday.(Reporting by Tom Westbrook in SYDNEY Additional reporting bySumeet Gaikwad in BENGALURUEditing by Byron Kaye and Aaron Sheldrick)

More News
16 May 2024 20:09

TRADING UPDATES: Bens Creek considers administration; Nexxen inks deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
16 May 2024 11:46

Angle reports promising results from Parsortix study

(Sharecast News) - Angle, the AIM-listed liquid biopsy company which specialises in circulating tumour cell (CTC) solutions, has announced the results of a clinical study which show that its Parsortix system could be used to predict progression-free survival in patients with ovarian cancer.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 10:52

AIM WINNERS & LOSERS: Fletcher King optimistic; Angle in Astra deal

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
3 May 2024 08:48

LONDON MARKET OPEN: Confident start before US jobs data

(Alliance News) - Stock prices in London opened higher on Friday, on the rising conviction that the afternoon's US jobs report will be softer, cooling some hawkish Federal Reserve interest rate expectations.

Read more
3 May 2024 07:58

Angle strikes supplier deal with AstraZeneca

(Sharecast News) - Liquid biopsy technology firm Angle has struck a supplier deal with pharmaceutical giant AstraZeneca to develop an androgen receptor detection assay to enhance prostate cancer studies.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
24 Apr 2024 17:06

CORRECT: No record close for FTSE 100; mixed trade in US

(Correcting day of the week in the opening sentence.)

Read more
24 Apr 2024 17:00

LONDON MARKET CLOSE: No record close for FTSE 100; mixed trade in US

(Alliance News) - Stock prices in London closed lower on Thursday, with the FTSE 100's recent rally taking a pause for breath, but not after hitting another record high.

Read more
24 Apr 2024 10:32

Angle shares jump on supplier agreement with with AstraZeneca

(Alliance News) - Angle PLC shares rose on Wednesday, after it signed a contract with AstraZeneca PLC.

Read more
24 Apr 2024 10:10

AIM WINNERS & LOSERS: Filtronic jumps as lifts outlook

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
22 Apr 2024 16:52

IN BRIEF: Angle granted patents in US and Europe for Cellkeep slide

Angle PLC - Surrey-based medical diagnostics provider - Says it has been granted a European and US patent for its CellKeep slide. "We are delighted to have secured intellectual property rights for our proprietary CellKeep slide in two major jurisdictions....This is a significant technology advancement for the [circulating tumor cell] liquid biopsy field and another step towards enabling biomarker-guided precision medicine for people with cancer," says Chief Executive Officer Andrew Newland. The CellKeep slide was developed by Angle to reduce cell loss during the transfer of CTCs to the microscope slide and to protect the morphology of the harvested cells.

Read more
22 Apr 2024 06:59

Angle granted European patent for CellKeep, US patent imminent

(Sharecast News) - Liquid biopsy specialist Angle announced on Monday that it has received a European patent for its 'CellKeep' slide, as it anticipated the imminent grant of an equivalent US patent application.

Read more
22 Jan 2024 18:03

IN BRIEF: Angle highlights supportive data for DNA analysis tool

Angle PLC - Surrey-based medical diagnostics provider - Announces publication of a peer-reviewed paper in a special issue of the journal - "Current Issues in Molecular Biology" Special Issue: Advanced Solutions for Cancer Therapy. Article brings together supporting evidence for the additional and complementary information that can be obtained from circulating tumour cells, demonstrating the value of a dual analyte approach for both CTCs and ctDNA (fragments of DNA released mainly by dying cells). Angle recently announced breakthrough data for real-time parallel next generation sequencing DNA analysis of both ctDNA and CTCs from a single tube of patient blood, using a pan-cancer panel run on an Illumina NGS system.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.